NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free SYRS Stock Alerts $5.43 +0.37 (+7.31%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$5.12▼$5.5650-Day Range$4.50▼$7.1352-Week Range$2.09▼$8.17Volume187,271 shsAverage Volume200,804 shsMarket Capitalization$145.13 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Syros Pharmaceuticals alerts: Email Address Syros Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside157.8% Upside$14.00 Price TargetShort InterestHealthy7.79% of Float Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment0.80Based on 7 Articles This WeekInsider TradingSelling Shares$747 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.78) to ($3.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.53 out of 5 starsMedical Sector237th out of 2,771 stocksPharmaceutical Preparations Industry71st out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Syros Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.79% of the float of Syros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 22.04%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSyros Pharmaceuticals has received a 64.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Syros Pharmaceuticals is -0.88. Previous Next 3.2 News and Social Media Coverage News SentimentSyros Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Syros Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SYRS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $747.00 in company stock.Percentage Held by Insiders12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Syros Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to grow in the coming year, from ($3.78) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Syros Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin AnalyticsDid Intel Just Dethrone Nvidia?Intel (INTC) just announced a brand-new AI venture - the Aurora supercomputer. This computer was specifically designed for artificial intelligence and is now the fastest AI-centered computer on the planet. You can get all the details here. About Syros Pharmaceuticals Stock (NASDAQ:SYRS)Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Read More SYRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRS Stock News HeadlinesMay 14 at 11:06 AM | msn.comSyros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77May 14 at 11:06 AM | msn.comSYRS Stock Earnings: Syros Pharmaceuticals Beats EPS for Q1 2024May 14 at 7:30 AM | businesswire.comSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateMay 12 at 2:44 AM | americanbankingnews.comSyros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on TuesdayMay 7, 2024 | businesswire.comSyros to Participate in Upcoming Investor ConferencesMay 7, 2024 | businesswire.comSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024April 10, 2024 | marketwatch.comSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for TamibaroteneApril 9, 2024 | msn.comSyros jumps on FDA fast track tag for leukemia drugApril 9, 2024 | markets.businessinsider.comFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid LeukemiaApril 9, 2024 | businesswire.comSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionApril 2, 2024 | businesswire.comSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 29, 2024 | investing.comEarnings call: Syros Pharmaceuticals strong Q4 and full year financialsMarch 29, 2024 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finance.yahoo.comSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene TrialsMarch 28, 2024 | finance.yahoo.comSyros Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsMarch 27, 2024 | markets.businessinsider.comSyros Pharmaceuticals earnings preview: what Wall Street is expectingMarch 27, 2024 | investorplace.comSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial DevelopmentsMarch 27, 2024 | businesswire.comSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateMarch 25, 2024 | finance.yahoo.comSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialMarch 20, 2024 | businesswire.comSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024March 16, 2024 | finance.yahoo.comSYRS Apr 2024 10.000 callMarch 11, 2024 | msn.comFibroGen appoints Deyaa Adib as Chief Medical OfficerFebruary 28, 2024 | finance.yahoo.comSYRS Jul 2024 2.500 callSee More Headlines Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/14/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYRS CUSIPN/A CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+157.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-164,570,000.00 Net Margins-1,656.34% Pretax Margin-1,656.34% Return on Equity-227.91% Return on Assets-75.60% Debt Debt-to-Equity Ratio2.07 Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$9.94 million Price / Sales14.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book6.87Miscellaneous Outstanding Shares26,728,000Free Float23,451,000Market Cap$145.13 million OptionableOptionable Beta1.75 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Richard A. Young Ph.D. (Age 70)Scientific Founder, Member of Scientific Advisory Board & Director Comp: $108.37kDr. David A. Roth M.D. (Age 61)Chief Medical Officer Comp: $679.52kMr. Conley Chee (Age 54)CEO, President & Director Dr. James E. Bradner M.D. (Age 52)Founder Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Jason Haas (Age 56)Chief Financial Officer Comp: $457.22kMs. Karen Hunady M.S.Director of Corporate Communications & Investor RelationsMr. Gerald E. Quirk Esq. (Age 56)J.D., Chief Legal Officer & Head of Business Development Comp: $127.07kMs. Lisa RobertsVice President of Human ResourcesMs. Kristin Stephens (Age 51)Chief Development Officer More ExecutivesKey CompetitorsSagimet BiosciencesNASDAQ:SGMTPDS BiotechnologyNASDAQ:PDSBDiaMedica TherapeuticsNASDAQ:DMACFibroGenNASDAQ:FGENRepare TherapeuticsNASDAQ:RPTXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 163,234 shares on 5/10/2024Ownership: 3.472%Acadian Asset Management LLCBought 17,162 shares on 5/10/2024Ownership: 0.064%Assenagon Asset Management S.A.Bought 144,869 shares on 4/24/2024Ownership: 0.636%David RothSold 150 sharesTotal: $747.00 ($4.98/share)Flagship Pioneering Inc.Bought 300,000 shares on 2/15/2024Ownership: 6.141%View All Insider TransactionsView All Institutional Transactions SYRS Stock Analysis - Frequently Asked Questions Should I buy or sell Syros Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYRS shares. View SYRS analyst ratings or view top-rated stocks. What is Syros Pharmaceuticals' stock price target for 2024? 2 equities research analysts have issued 12-month price objectives for Syros Pharmaceuticals' shares. Their SYRS share price targets range from $13.00 to $15.00. On average, they anticipate the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 157.8% from the stock's current price. View analysts price targets for SYRS or view top-rated stocks among Wall Street analysts. How have SYRS shares performed in 2024? Syros Pharmaceuticals' stock was trading at $7.79 at the beginning of 2024. Since then, SYRS stock has decreased by 30.3% and is now trading at $5.43. View the best growth stocks for 2024 here. When is Syros Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our SYRS earnings forecast. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its earnings results on Wednesday, March, 27th. The company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $0.04. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $2.40 million. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative trailing twelve-month return on equity of 227.91%. When did Syros Pharmaceuticals' stock split? Shares of Syros Pharmaceuticals reverse split on the morning of Monday, September 19th 2022. The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Nancy Simonian's approval rating as Syros Pharmaceuticals' CEO? 3 employees have rated Syros Pharmaceuticals Chief Executive Officer Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among the company's employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE). When did Syros Pharmaceuticals IPO? Syros Pharmaceuticals (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.47%), Assenagon Asset Management S.A. (0.64%) and Acadian Asset Management LLC (0.06%). Insiders that own company stock include David Roth, Eric R Olson, Srinivas Akkaraju and Timothy Tyson. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYRS) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.